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Abstract
α-synuclein (α-syn) is a main component of Lewy bodies (LB) that occur in many neurodegenerative diseases, including
Parkinson's disease (PD), dementia with LB (DLB) and multi-system atrophy. α-syn mutations or amplifications are
responsible for a subset of autosomal dominant familial PD cases, and overexpression causes neurodegeneration and
motor disturbances in animals. To investigate mechanisms for α-syn accumulation and toxicity, we studied a mouse
model of lysosomal enzyme cathepsin D (CD) deficiency, and found extensive accumulation of endogenous α-syn in
neurons without overabundance of α-syn mRNA. In addition to impaired macroautophagy, CD deficiency reduced
proteasome activity, suggesting an essential role for lysosomal CD function in regulating multiple proteolytic pathways
that are important for α-syn metabolism. Conversely, CD overexpression reduces α-syn aggregation and is
neuroprotective against α-syn overexpression-induced cell death in vitro. In a C. elegans model, CD deficiency
exacerbates  α-syn accumulation while its overexpression is protective against α-syn-induced dopaminergic
neurodegeneration. Mutated CD with diminished enzymatic activity or overexpression of cathepsins B (CB) or L (CL) is
not protective in the worm model, indicating a unique requirement for enzymatically active CD. Our data identify a
conserved CD function in α-syn degradation and identify CD as a novel target for LB disease therapeutics.
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Introduction
Patients with α-synuclein (α-syn) A53T, A30P, E46K
mutations or gene amplification develop typical Parkin-
son's disease (PD) and often an associated dementia[1].
However, in > 90% of PD cases, and almost all dementia
with Lewy body (DLB) and Lewy body variant of Alzhe-
imer's disease (LBVAD) cases, α-syn aggregation occurs
yet without a clear evidence of mutation or up-regulation
of α-syn mRNA transcription. Therefore, impaired α-syn
clearance may play a more important role than α-syn
overexpression in neuronal α-syn accumulation and neu-
rodegenerative disease pathogenesis.
Experiments in vitro have shown that α-syn can be cleared
by the cytosolic ubiquitin-proteasome system (UPS), and/
or lysosome-mediated autophagic pathways[2]. The UPS
degrades short-lived, misfolded and/or damaged proteins
via an ubiquitin-dependent signaling pathway. Macroau-
tophagy is initiated by de novo synthesis of double mem-
brane vesicles in the cytoplasm. These vesicles encircle
long-lived or damaged proteins or organelles by an
unknown signaling mechanism and deliver these cargos
to lysosomes for degradation. Chaperone-mediated
autophagy (CMA) is initiated by chaperones binding to
KFERQ-consensus sequence-containing cytosolic proteins
followed by delivery to the lysosomes via lysosomal mem-
brane LAMP-2a receptors. Wildtype α-syn has a pentapep-
tide sequence that can serve as a CMA recognition motif
and can be translocated to the lysosome, while dopamine
modified or pathogenic A53T and A30P mutant α-syn
block CMA [3,4].
Lysosomal function declines with age in the human
brain[5]. Accumulation of autophagic vacuoles (AVs) has
been reproducibly observed in postmortem AD and PD
patient brains compared to normal controls, consistent
with either an overproduction of AVs or a deficit in
autophagolysosomal clearance[6]. Enhancing macroau-
tophagy by either mTOR-dependent or independent
mechanisms can help clear aggregation-prone proteins,
including huntingtin, A53T and A30P mutant α-syn [7,8].
However, because both macroautophagy and CMA are
dependent on intact lysosomes, enhancing macroau-
tophagy may not be effective in clearing potentially neu-
rotoxic proteins if lysosomal function is impaired.
Understanding the role of lysosomal enzymes in α-syn
clearance may provide new strategies for LBVAD, DLB,
and PD therapy.
Cathepsin D (CD) is the principal lysosomal aspartate
protease and a main endopeptidase responsible for the
degradation of long-lived proteins [9,10], including α-
syn[11]. CD is expressed widely in the brain, including the
cortex, hippocampus, striatum, and dopaminergic (DA)
neurons of the substantia nigra (SNr)[12]. CD is synthe-
sized as a precursor with a signal peptide cleaved upon its
insertion into endoplasmic reticulum[13]. The CD
zymogen is activated in an acidic environment by cleavage
of the pro-peptide. CD is also up-regulated in AD brains
as an early event, but whether CD up-regulation is coinci-
dental, disease promoting, or compensatory is
unclear[14].
CD gene (Ctsd) homozygous inactivation was reported to
cause human congenital neuronal ceroid lipofuscinosis
(NCL) with postnatal respiratory insufficiency, status epi-
lepticus, and death within hours to weeks after birth[15].
These patients had severe neurological defects at birth and
neuronal α-syn accumulation was not examined. Another
patient with significant loss of CD enzymatic function
(7.7% Vmax from patient fibroblast lysates compared to
controls) due to compound heterozygous missense muta-
tions developed childhood motor and visual distur-
bances, cerebral and cerebellar atrophy, and progressive
psychomotor disability[16]. Conceivably, milder forms of
CD deficiency could predispose to late onset neurodegen-
erative disorders, including AD and PD. Parkinsonism has
been noted in lysosomal tripeptidyl peptidase I deficient
patients[17], adult forms of NCL patients[18], and Gau-
cher disease patients[19]. α-syn aggregation has been
reported in both neurons and glia in several lysosomal
disorders, such as Gaucher disease[20], Niemann-Pick
disease[21], GM2 gangliosidosis, Tay-Sachs, Sandhoff dis-
ease, metachromatic leukodystrophy, and beta-galactosia-
lidosis[22].
Significant α-syn accumulation has not been previously
reported in mouse models of proteolytic disorders involv-
ing proteasomes, autophagy or other lysosomal proteases
[23-26]. Here we report a robust α-synucleinopathy in CD
deficient mice, despite the compensatory up-regulation of
other lysosomal proteases, and the absence of an increase
of α-syn mRNA expression. We found that proteasome
activities are significantly reduced in the CD-deficient
brain, whereas several key UPS factors are either normal or
up-regulated, indicating crosstalk between lysosomal and
proteasomal activities at the levels of signaling rather than
a reduction of protein levels. Finally, we demonstrate that
CD, but not Cathepsin B (CB) or Cathepsin L (CL), over-
expression reduces α-syn aggregation and provides potent
neuroprotection from α-syn-induced neuron death in
vitro and in vivo.
Results
CD deficient mice exhibit extensive accumulation of α-syn 
in neurons
To investigate the involvement of lysosomal functions in
α-syn clearance, we analyzed mice deficient in CD, previ-
ously generated by a targeted insertion of the neo marker
in exon 4[27]. CD-deficient (Ctsd-/-) mice die at approxi-Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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mately postnatal day 26 (p26) due to a combination of
nervous system and systemic abnormalities. Extensive
neuron death resulting from activation of both apoptotic
and non-apoptotic pathways has been observed in these
mice [27-31]. We examined brains from p21 and p25
Ctsd-/- mice and found significant α-syn accumulation in
neuronal cell bodies in p25 Ctsd-/- but not wildtype cortex
(Fig. 1a). In contrast to the brains of human lipidoses
patients[32] where α-syn aggregates are found in both
neurons and glia and co-localize with lipids, in Ctsd-/-
brains  α-syn accumulations do not co-localize with
autofluorescent lipofuscin (data not shown).
Furthermore, α-syn accumulations in Ctsd-/- brains were
present in cells co-expressing the neuron marker, neuro-
nal nuclear antigen (NeuN), but not in glial fibrillary
acidic protein (GFAP)-immunoreactive astrocytes (Fig.
1b–c). Accumulation of ubiquitinated proteins also
occurs in Ctsd-/- cortex (Fig. 1a). A relatively small fraction
of neurons (~5%) with intense accumulated α-syn immu-
nostaining also exhibit co-localization with intense accu-
mulated ubiquitin staining, consistent with the
observation that a small fraction of α-syn in LB is ubiqui-
tinated [33-36]. Correspondingly, we found elevated lev-
els of high molecular weight but not monomeric α-syn,
and high molecular weight ubiquitinated proteins in both
TritonX-100 soluble and insoluble extracts from the cor-
tex of Ctsd-/- mice by western blot analyses compared to
Ctsd+/+ mice, similar to what occurs in LB diseases (Fig.
1d–e). Truncated 12 kDa and 10 kDa α-syn fragments are
reduced in Ctsd-/- extracts (Fig. 1d–e).
Antibody pulldown experiments indicate that a small frac-
tion of accumulated α-syn in Ctsd-/- brains is mono-ubiq-
uitinated (Fig. 1f). These results are consistent with a
small fraction of accumulated α-syn in Ctsd-/- brains
being mono-ubiquitinated [33-36]. Ubiquitin immunos-
taining is present in nearly all neurons with variable inten-
sity. 5% of those neurons with intense accumulated
ubiquitin staining also exhibit intense accumulated α-syn
immunostaining in Ctsd-/- brain sections. Conversely, 5%
of neurons with intense accumulated α-syn immunos-
taining also exhibit intense accumulated ubiquitin stain-
ing. p21 Ctsd+/+ and Ctsd-/- brains do not exhibit
considerable difference in α-syn immunostaining inten-
sity or protein level by western blot analyses. However,
ubiquitin accumulation occurs as early as p21 in Ctsd-/-
cortical extracts compared to wildtype cortical extracts
(Fig. 1g).
Immunostaining with synphilin antibodies have not
detected "aggregation-like" structures in the cell body
where α-syn is. Nor did we observe increased synphilin in
western blot analyses. Thus the α-syn accumulation is
unlikely to be induced by synphilin accumulation in Ctsd-
/- brains. The cytoplasmic microtubule-associated pro-
tein, tau, did not accumulate in Ctsd-/- cortex at p25 com-
pared to wildtype cortex at p25 (data not shown),
suggesting that CD deficiency does not have a general
effect on the accumulation of all cytoplasmic proteins.
In human LB, 95% of the insoluble α-syn is phosphor-
ylated [33-35,37,38]. We found that anti-phospho-α-syn
antibody (from Dr. Iwatsubo [33,36,38]) did not recog-
nize the intensely immunoreactive accumulated α-syn in
Ctsd-/- brains, although numerous neurons in both
wildtype and Ctsd-/- brains exhibited labeling with this
antibody. Whether this antibody lacks specificity when
used in mouse brain sections or the accumulated α-syn in
Ctsd-/- brain is simply not phosphorylated cannot be
determined from this immunohistochemical study. West-
ern blot analyses indicate that a few immunoreactive
bands are increased in Ctsd-/- extracts compared to
wildtype extracts.
Intense α-syn immunoreactive accumulations are outside 
of autophagosomes and lysosomes in affected neurons
Prior studies found autophagosomes start to accumulate
in Ctsd-/- brains as early as p1, compared to Ctsd+/+ age-
matched controls [28,30]. Furthermore, CB immunos-
taining as well as enzymatic activities are increased as
early as p21 in Ctsd-/- brains [28,30]. Electron microscopy
studies demonstrated that CB was associated with irregu-
larly shaped and membrane-bound structures containing
electron-dense materials, characterizing them as lyso-
somes in Ctsd-/- brains [28,30]. We found that α-syn
accumulation does not become prominent until near p25
in Ctsd-/- brains. α-syn accumulation occurs in only a sub-
population of neurons that exhibit enhanced Atg8
(AuTophaGy8)/LC3 (light chain 3) staining, indicating
that AV accumulation precedes α-syn accumulation (Fig.
2a). We also found that α-syn accumulations are adjacent
to, but do not overlap with, immunoreactivity for the AV-
associated protein Atg8/LC3 or the lysosomal associated
protein CB, suggesting that α-syn accumulation formed
outside of autophagosomes and lysosomes (Fig. 2b). Neu-
ronal populations immunoreactive for the apoptotic
marker, cleaved caspase-3, are distinct from those with
intense α-syn accumulation (Fig. 2c).
α-syn accumulation is not due to up-regulation of its 
mRNA, and appears despite compensatory up-regulation 
of other proteases
While bulk protein degradation appears to be normal in
Ctsd-/- mice[27], we found that α-syn mRNA is down-reg-
ulated in Ctsd-/- brains at p25 when α-syn accumulation
occurs (Fig. 3a). This is consistent with the finding that α-
syn mRNA is either unchanged or down-regulated in the
majority of sporadic PD cases[39], indicating that α-syn
accumulation is unlikely to be the consequence of ele-Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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vated gene expression. Prior studies reported that CB but
not CL protein is up-regulated in Ctsd-/- brains at p23[28].
To better understand the role of CD in selective protein
degradation and PD, we analyzed the expression of genes
encoding other brain-enriched lysosomal proteases,
autophagy-associated factors, proteasome subunits, and
genes linked to familial PD. Interestingly, genes encoding
other lysosomal cathepsins B, L, F and H (Ctsb, Ctsl, Ctsf,
and Ctsh) mRNAs are all up-regulated at p25 (Fig. 3a).
This result may suggest a common transcription regula-
tory mechanism for these cathepsins in response to CD
deficiency. Alternatively, the influx of macrophages or
microglia into the Ctsd-/- brain at this age may lead to an
increase in cathepsin mRNA expression[40]. We also
determined that accumulation of autophagosomes in
Ctsd-/- neurons is accompanied with transcriptional up-
regulation of Atg7 but not Atg12 (Fig. 3a). Both Atg7 and
Atg12 are involved in an ubiquitin-like activity important
for autophagosome expansion. Up-regulation of Atg7
may indicate an increase of autophagosome production
in addition to a blockade of autophagy completion
[28,38,40]. mRNA of Park2 which encodes Parkin, muta-
tion of which has been found in a subset of autosomal
recessive PD;UCHL1, mutation of which has been found
in a subset of autosomal dominant PD; and Psmb7 which
encodes proteasome 20S core β2 subunit are also mod-
estly up-regulated in response to CD deficiency, indicating
a compensatory response to CD deficiency at the level of
gene transcription (Fig. 3a).
CD deficiency reduces proteasome activities
In addition to deficient macroautophagy, we found an
accumulation of GAPDH, a substrate of CMA (Fig. 3b).
Interestingly, we also found reduced proteasome activity
in Ctsd-/- brain extracts (Fig. 3c), suggesting a functional
interaction between the two major α-syn clearance
machineries, lysosomes and proteasomes. Accumulation
of ubiquitinated proteins in Ctsd-/- brain appears at p21
compared to that in wildtype brains (Fig. 1g, 3e), when
proteasome activities are unaltered as determined by the
proteasome activity assay (data not shown). So far, none
of the proteasome-related proteins we examined, includ-
ing UCHL1, a gene mutated in familial PD and a ubiqui-
tin hydrolase and E3 ligase; Usp14, a key
deubiquitination enzyme; Rpt3, an ATPase regulatory
subunit, a4 subunit that is important for the gating into
the 20S core particle, and b1 subunit that is part of the
proteasome core, were significantly changed as deter-
mined by western blot analyses in Ctsd-/- brains (Fig. 3d).
Overexpression of CD reduces α-syn aggregation in 
mammalian cells
To further understand how CD activity influences α-syn
homeostasis, we examined whether enhancing CD expres-
sion can reduce α-syn aggregation. We adopted the simple
culture system developed by McLean and colleagues in
which an α-syn-green fluorescent protein (GFP) fusion
protein (α-syn-GFP) forms visible aggregates in cells when
co-expressed with synphilin[41]. We transfected H4 neu-
roglioma cells with α-syn-GFP, synphilin, and CD. As a
control, cells were transfected with α-syn-GFP, synphilin
and empty vector pcDNA3.1. Approximately 50% of con-
trol transfected cells exhibited α-syn aggregates, consistent
with published findings[41]. Remarkably, transfection of
CD together with α-syn-GFP and synphilin led to less
than 20% of transfected cells exhibiting α-syn aggregates
(Fig. 4a). To address the issue of whether CD could affect
synphilin levels, we performed immunocytochemistry
α-syn accumulates in neuronal cell bodies in p25 Ctsd-/- cortex Figure 1 (see previous page)
α-syn accumulates in neuronal cell bodies in p25 Ctsd-/- cortex. a. Immunohistochemical detection of α-syn and ubiq-
uitin in p25 Ctsd+/+ (+/+) and Ctsd-/- (-/-) cortex. Scale bar = 20 micron. Arrows point to intense α-syn and ubiquitin immuno-
reactive cells. b. α-syn accumulation occurs in NeuN+ neuronal cell bodies. α-syn = Cy3 (red), NeuN = FITC (green). 
Wildtype (+/+) brains exhibit diffuse α-syn staining consistent with a synaptic distribution. Ctsd-/- brains showed neurons with 
cytoplasmic accumulation of α-syn immunoreactivity. Scale bar = 10 micron. c. α-syn does not exhibit pronounced accumula-
tion in GFAP+ cells. α-syn = Cy3 (red). GFAP = FITC (green). Scale bar = 10 micron. d. Accumulation of high molecular weight 
α-syn and ubiquitinated proteins in both the TritonX-100 soluble and the insoluble fractions of the Ctsd-/- mice. Intensity of α-
syn monomer, α-syn oligomers, and Ub-positive smears were quantified and compared between Ctsd+/+ and Ctsd-/- extracts. 
Truncated 12 kDa and 10 kDa α-syn fragments are reduced in Ctsd-/- extracts. e. Quantification of the western results. n = 3 
mice each genotype. *p < 0.05 compared to Ctsd+/+ by Student t-test. S = TritonX-100 soluble. IS = TritonX-100 insoluble. f. 
A small fraction of accumulated α-syn in Ctsd-/- brains being mono-ubiquitinated. Western blot analysis of TritonX-100 soluble 
Ctsd-/- brain extract (Input), pulldown product by a polyclonal α-syn antibody C-20 (Santa Cruz) (middle lane), and pulldown 
product by a same-isotype control antibody (IgG). Immunoblot was probed with mAb1510 against ubiquitin. Shown are the 25 
kDa bands of ubiquitin immunoreactivity that were pulled down by the C-20 anti-α-syn antibody. g. Western blot analysis of 
ubiquitin with p21 Ctsd+/+ and Ctsd-/- cortical extracts. The intensity of each lane was quantified and shown in the bar graph. *p 
< 0.05 Student t-test. h. Western blot analyses of Ctsd+/+ and Ctsd-/- cortical extracts, together with human DLB brain 
extracts using anti-phospho-α-syn antibody provided by Dr. Iwatsubo [33,36,38]. Arrows indicate positions of immunoreactive 
bands that are increased in Ctsd-/- mice and the position of α-syn monomer.Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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α-syn accumulation does not co-localize with LC3 or CB immunoreactivity and is independent of active caspase-3 immunore- activity Figure 2
α-syn accumulation does not co-localize with LC3 or CB immunoreactivity and is independent of active cas-
pase-3 immunoreactivity. a. Immunostaining with Atg8/LC3 and α-syn antibodies shows that LC3 staining is increased in 
Ctsd-/- mice compared to Ctsd+/+ mice, and intense α-syn immunoreactivity does not colocalize with LC3 immunoreactivity 
(arrows, p25). LC3 = FITC (green). α-syn = Cy3 (red). Arrowheads point to cells with high LC3 immunoreactivity but without 
intense α-syn immunostaining. b. α-syn accumulation does not overlap with CB immunoreactivity. CB = FITC (green). α-syn = 
Cy3 (red). Arrow points to α-syn intense immunoreactive staining adjacent to CB staining. c. Neurons with active caspase-3 
immunoreactivity do not exhibit intense α-syn immunoreactivity in Ctsd-/- brains. α-syn = FITC (green). Active caspase-3 = 
Cy3 (red). Arrows point to active caspase-3 immunoreactivity. Scale bar = 10 micron. n = 3 mice each genotype.
a
b
c
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Deficits of proteasomes in CD deficient mice Figure 3
Deficits of proteasomes in CD deficient mice. a. α-syn (Snca) mRNA is down-regulated in CD deficient brains compared 
to wildtype control brains. Ctsb, Ctsl, Ctsf, Ctsh, Atg7, UCHL1, Park2, and Psmb7 mRNA levels are up-regulated. Atg12 and Psmb6 
mRNA levels appear to be normal. b. Western blot analyses show an increase of steady state GAPDH, a CMA substrate. n = 3 
p25 brain. *p < 0.05 by Student t-test, compared between Ctsd+/+ and Ctsd-/- brains. c. Extracts from Ctsd-/- cortex exhibit 
reduced proteasome activities compared to Ctsd+/+ as indicated by assays with trypsin-like fluorigenic substrate (VGR-AMC, 
reaching maximum at 60 min), chymotrypsin-like fluorigenic substrate (Z-GGL-AMC, reaching maximum at 120 min), and pep-
tidylglutamyl peptide-like fluorigenic substrate (Suc-LLVY-AMC, reaching maximum at 120 min). The activities that are inhibita-
ble by the proteasome inhibitor lactacystin were quantified. n = 3 mice each genotype. *p < 0.05 by Student t-test. d. Normal 
expression of proteins involved in UPS. Western blot analyses of UCHL1, Usp14, Rpt3, α4 and β1 indicate that these UPS fac-
tors are expressed normally in Ctsd+/+ and Ctsd-/- cortical extracts. Actin immunoblotting was used as a loading control. n = 3 
mice each genotype. e. A diagram regarding onset of relative pathologies.Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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Figure 4 (see legend on next page)
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experiments to compare α-syn+synphilin+vector trans-
fected cells and α-syn+synphilin+CD transfected cells. We
chose this approach because very low transfection effi-
ciency was achievable (less than 5%) in this aggregation
assay. Thus, we cannot perform western blot analyses or
quantitative RT-PCR assays for this experiment. Double
immunostaining for CD and the V5 epitope tag on syn-
philin and double immunostaining for CD and α-syn
were performed (Figs. 4b and 4c). We quantified the
number of transfected cells with α-syn aggregates and
those without α-syn aggregates. Many more cells that were
transfected with synphilin+α-syn+vector exhibited α-syn
aggregates in comparison to cells transfected with synphi-
lin+α-syn+CD. Nonetheless, the levels of synphilin
immunostaining were indistinguishable in cells trans-
fected with synphilin+α-syn+vector versus cells trans-
fected with synphilin+α-syn+CD. This is true in cells with
or without aggregates. We conclude that CD reduction of
α-syn aggregation is unlikely to be secondary to a reduc-
tion in synphilin levels.
Overexpression of CD is neuroprotective against α-syn 
toxicity in mammalian cells
Excessive α-syn induces neuron death in cell cultures, and
in a variety of genetic and viral delivery based animal
models [42-45]. To examine the potential of elevating CD
level as a means to reduce α-syn-induced cell death, we
transfected human neuroblastoma SHSY5Y cells with α-
syn-GFP, in the absence or presence of increased CD
expression (Fig. 5a). Similar to previous studies of α-syn
overexpression in yeast, worms and rat neurons[44], we
found that overexpression of α-syn-GFP induced signifi-
cant cell death in SHSY5Y cells. Co-transfection of human
CD provided significant protection against α-syn-GFP
overexpression-induced cell death (Fig. 5a). Quantitative
real-time RT-PCR confirmed the up-regulation of α-syn
mRNA by α-syn transfection, and lack of effect of CD
transfection on α-syn mRNA level (Fig. 5b). Furthermore,
co-expression of CD with α-syn-GFP in human neuroblas-
toma SHSY5Y cells produced a cleavage product of α-syn-
GFP and reduced endogenous monomeric 17 kDa α-syn
(Fig. 5c).
α-syn point mutation at the major CD cleavage site results 
in resistance to CD neuroprotection
α-syn is rich in hydrophobic amino acids (52%) and is
natively unfolded. CD has a known specificity in recogniz-
ing hydrophobic residues[11]. Although α-syn contains
many putative CD cleavage sites, the main cleavage occurs
at Y125[11]. We found that CD is also protective against
PD-causing mutant α-syn-GFP induced-cell death in
SHSY5Y cells (Fig. 5d). In contrast, mutating α-syn-GFP at
the putative CD cleavage site Y125[11] results in an α-syn
mutant that induces cell death that resists neuroprotec-
tion by elevated CD (Fig. 5d). Furthermore, CD is ineffec-
tive at attenuating chloroquine- or staurosporine-induced
cell death (Fig. 5d). Western blot analyses confirmed the
up-regulation of transfected genes (Fig. 5e).
Overexpression of CD is neuroprotective in C. elegans
To further investigate the role of CD activity in α-syn clear-
ance in vivo, we generated transgenic C. elegans expressing
a human α-syn and GFP fusion protein in body wall mus-
cle cells. In these worms, human α-syn::GFP forms aggre-
gates as worms develop and age (Fig. 6a). As in
mammalian cells[46], co-expression of the worm TOR-2
protein chaperone ameliorated the formation of α-
syn::GFP aggregates (Fig. 6b). Importantly, this estab-
lished a genetic background within which enhancement
of α-syn aggregation could be more readily visualized by
RNA interference (RNAi). Using bacterial RNAi feeding to
specifically target the C. elegans ortholog of Ctsd, we
knocked down Ctsd  in  α-syn::GFP + TOR-2 transgenic
worms. RNAi targeting of Ctsd led to a return of fluores-
cent aggregates over time (Fig. 6c), and RNAi of Ctsd did
not affect tor-2 mRNA levels as examined by real-time RT-
CD reduces α-syn aggregation Figure 4 (see previous page)
CD reduces α-syn aggregation. a. CD reduces α-syn aggregation in an aggregation assay. 50% of the cells transfected with 
α-syn-GFP, synphilin and empty vector exhibited visible α-syn aggregates. Co-transfection of CD together with α-syn-GFP and 
synphilin reduced the number of cells with visible α-syn aggregates to 20%. n = 3 independent transfection, each in quadrupli-
cate. *p < 0.05 compared to absence of exogenous CD by Student t-test. b. Double immunostaining for CD and α-syn in the 
aggregation assay after transfection of H4 cells with α-syn+synphilin+vector and α-syn+synphilin+CD. Many more cells trans-
fected with synphilin+α-syn+vector have α-syn aggregates than cells transfected with synphilin+α-syn+CD. α-syn = red; CD = 
green. Higher magnification images of the boxed areas are shown at the left-most panel. α-syn aggregates tended to be found 
in cellular areas with low levels of CD staining, in H4 cells with either α-syn+synphilin+vector or α-syn+synphilin+CD. Scale 
bar = 25 micron. Arrows point to α-syn aggregates. c. Double immunostaining for CD and the V5 tag of synphilin in the aggre-
gation assay after transfection of H4 cells with α-syn+synphilin+vector and α-syn+synphilin+CD. Many more cells transfected 
with synphilin+α-syn+vector have α-syn aggregates than cells transfected with synphilin+α-syn+CD. Synphilin = red; CD = 
green. The levels of synphilin immunostaining were indistinguishable in cells transfected with synphilin+α-syn+vector versus 
cells transfected with synphilin+α-syn+CD. This is true in cells with or without aggregates. Scale bar = 25 micron. Arrows 
point to α-syn aggregates.Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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PCR (Fig. 6f). Thus, Ctsd deficiency led to α-syn aggrega-
tion in both mice and worms.
We further investigated whether human CD attenuates the
loss of dopaminergic neurons in a C. elegans model of α-
syn-induced neurodegeneration[44]. Overexpression of
α-syn led to DA neuron death, as evidenced by the finding
that only 16% of 7 d old adult α-syn expressing worms (n
= 270 worms analyzed) displayed normal numbers of DA
neurons (Fig. 6d, g). In contrast, co-overexpression of
human CD significantly protected against DA neurode-
generation, since 30% of same-staged animals (n = 270)
exhibited wildtype DA neurons (Fig. 6e, g; p  < 0.001,
Fisher Exact Test). Overexpression of enzymatic mutants
of CD (D295R and F229I) [16,47], or related human
cathepsin gene products, CB or CL, did not attenuate DA
neuron death in this in vivo assay (Fig. 6g), thereby sug-
gesting a specific role of CD in neuroprotection against α-
syn-induced DA cell death, as well as an essential role of
CD enzymatic activity in this neuroprotection.
Discussion
Our results demonstrate that CD deficiency leads to sig-
nificant accumulation of α-syn that is concentrated in
neuronal cell bodies, despite the up-regulation of multi-
ple lysosomal cathepsin genes. α-synucleinopathy arises
from CD dysfunction, either directly due to deficient pro-
teolytic cleavage, and/or indirectly as a consequence of
compromised proteasome activity. Most significantly, we
further demonstrated that CD overexpression protects
neurons from α-syn aggregation and α-syn-induced death
both in mammalian cells and in C. elegans. These findings
suggest that targeted CD therapy may inhibit or reverse LB
disease-associated neuropathology.
The α-syn accumulations in Ctsd-/- brains are neuronal
and perinuclear. Although Ctsd-/- brain extracts exhibited
increased immunoreactive protein species recognized by
the anti-phospho-α-syn antibody that specifically recog-
nizes human LB[36], α-syn accumulations in Ctsd-/-
brains could not be detected by this antibody that specifi-
cally recognizes human LB despite that they were success-
fully used in our hands to demonstrate LB-specific
staining of human PD specimen (data not shown). Only
5% of neurons exhibited intense immunoreactivity for
both α-syn and ubiquitin suggesting their accumulation,
an observation in accordance with that only a small frac-
tion of α-syn is ubiquitinated in human LB [33-36]. α-syn
accumulations are adjacent to but not overlapping with
autophagosomal or lysosomal markers, suggesting an
attenuation of these complexes and organelles in encir-
cling accumulated α-syn in the Ctsd-/- brains. Where α-
syn unfolds and forms oligomers, and whether CD
reduces a specific sub-population of α-syn protofibrils or
other small assemblies of α-syn require further investiga-
tion.
α-syn gene triplication is causative in a subset of PD,
which suggests that increasing α-syn gene dosage pro-
motes DA neuron death in these patients[1]. Overproduc-
tion of α-syn via AAV delivery induces DA neuron death
in rodents[45]. CD deficiency induced by aging, genetic
polymorphism, or environmental toxins may predispose
animals to an earlier onset of spontaneous neuron death,
or exacerbate neurotoxin or α-syn overproduction-
induced DA neuron loss, in comparison to wildtype con-
trol mice. Furthermore, although Ctsd-/- mice die approx-
imately p26 without apparent tau or beta amyloid
accumulation in the brain (data not shown), we cannot
CD reduces α-syn toxicity Figure 5 (see previous page)
CD reduces α-syn toxicity. a. Enhanced CD expression protects against α-syn overexpression-induced cell death. GFP was 
visualized under the fluorescence microscope and demonstrated more survival cells after co-transfection of GFP-α-syn and CD 
compared to transfection with GFP-α-syn alone. Viable cells were counted by trypan blue exclusion method. b. mRNA of α-
syn is unchanged by CD transfection. SHSY5Y cells were transfected with vector alone, CD, α-syn, or α-syn+CD. Paired Stu-
dent t-tests were conducted on RQ values for each group to determine significance. c. Western blot analyses indicate that CD 
transfection results in truncation of α-syn-GFP (the appearance of a band below the full-length 37 kDa band), and a reduction 
of endogenous 17 kDa α-syn monomers. CD is synthesized as a prepropeptide (53 kDa); the signal peptide is cleaved upon CD 
insertion into the endoplasmic reticulum (47 kDa). The CD zymogen is then activated in the acidic lysosomal environment to 
produce the 32 and 14 kDa products [13,47]. d. Enhanced CD expression reduces A53T and A30P mutant α-syn-induced cell 
death, but does not reduce Y125A mutant α-syn-, 10 μM chloroquine-, or 2 μM staurosporine-induced cell death. For a-d, *p 
< 0.05 compared to control (CTL); †p < 0.05 compared to otherwise identical transfection except without CD. n = 3 transfec-
tion for each experimental conditions. Student t-test was used. e. Increased protein levels correlate with transfection of 
respective cDNAs. SHSY5Y cells were transfected with control vector, or respective cDNA in each lane. The respective anti-
bodies used for the immunoblots are at the left side of the gel images. Mutated α-syn-GFP were produced. CD transfection did 
not produce significant truncation intermediate products on the mutated α-syn-GFP, suggesting that the protection against 
A53T and A30P may be via alteration of their intracellular targeting rather than direct cleavage. CD 53 kDa and 47 kDa precur-
sors and the 32 kDa mature product are shown. Actin immunoblot was used as a loading control.Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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exclude the possibility that partial loss of CD may also
affect tau or beta amyloid clearance.
We found significant down-regulation of proteasome
activities in Ctsd-/- brains. The reduction of proteasome
activity may be due to reduced expression of UPS regula-
tors and proteasome subunits, inactivating post-transla-
tional modification of these proteins, or specific
inhibitory signaling by the accumulated ubiquitinated
proteins. Crosstalk between protein degradation path-
ways is potentially important in neurodegenerative dis-
ease pathogenesis since inhibition of proteasomes up-
regulates lysosomal enzymes[48], and enhancing proteas-
ome function alleviates autophagy defects[49]. Further-
more, α-syn overexpression in mammalian cells affects
proteasome activity, macroautophagy as well as lyso-
somal functions[50]. Lysosomal storage disorders and lys-
osomal cysteine protease inhibitor E64 treatment were
previously shown to down-regulate UCHL1[51], how-
ever, such is not the case in Ctsd-/- brains in our study,
indicating a distinct mechanism of CD deficiency-induced
proteasome dysfunction. GAPDH accumulation may be a
consequence of impaired CMA[3], because Ctsd-/- cells
are compromised in lysosomal function[3]. Alternatively,
GAPDH elevation may represent an ultimately futile com-
pensatory signal that elevates macroautophagy initiation
as previously suggested in HeLa cells[52]. Additionally,
GAPDH elevation may promote the formation of protein
inclusions [53,54].
The overproduction of α-syn has been shown to cause cell
death in many studies through a variety of mechanisms,
including a compromise in synaptic vesicle function, the
induction of ER stress, Golgi fragmentation, mitochon-
drial dysfunctions and proteasome dysfunction [44,55-
58]. However, cell death in these studies required massive
overproduction of α-syn. Even in these conditions, the
challenge has been to determine whether the intermediate
species of α-syn are the most toxic to neurons. It remains
possible that the α-syn aggregates in sporadic PD are not
causative to DA neuron death, but rather a compensatory
activity to attenuate DA neuron death, or a mere
bystander effect in DA neuron death. The comparison of
different mutant forms of α-syn in their propensity in
forming fibrils and their toxicity was carried out in yeast
and the rate of fibrillization did not positively correlate
with toxicity[59]. α-syn can interact with many other pro-
teins[60], but whether these interactions elicit cytoprotec-
tive versus death-inducing effects remains to be
elucidated. Other observations suggest that LB formation
may be a mechanism to sequester toxic α-syn species and
thus exert a protective function [61-63]. Our observation
that α-syn accumulates in Ctsd-/- brains does not distin-
guish its role in promoting or attenuating death in Ctsd-/-
brains in vivo. We did not observe neurons with concur-
rent activation of caspase-3 and α-syn accumulation (Fig.
2). This may indicate that α-syn accumulation and capase-
3 activation are with different time course. Alternatively,
our observation may suggest that? certain forms of α-syn
accumulation induce non-apoptotic cell death, or even
compensatory neuroprotection.
α-syn knockout mice are resistant to MPTP-induced DA
neuron death [64-66]. Reduction of α-syn is neuroprotec-
tive in multiple animal models [67,68]. Regardless of the
precise mechanism for CD deficiency induced α-synuclei-
nopathy, our finding that enhanced expression of CD is
neuroprotective against α-syn aggregation and toxicity,
both in worms and in mammals, provides a basis for
future investigation of whether delivery of CD to the cen-
tral nervous system in animal models of LB diseases can
help alleviate protein aggregation and toxicity, and
thereby serve as a previously unexplored target for disease
therapy.
Increased CD expression reduces α-syn-toxicity in C. elegans Figure 6 (see previous page)
Increased CD expression reduces α-syn-toxicity in C. elegans. a. RNAi knockdown of a C. elegans Ctsd ortholog wors-
ens aggregation of human α-syn in vivo. Isogenic worm strain expressing α-syn::GFP alone (a) or with TOR-2 (b), in body wall 
muscle cells of C. elegans. The presence of TOR-2, a protein with chaperone activity, attenuates the misfolded α-syn protein 
(b). When worms expressing α-syn::GFP + TOR-2 are exposed to CD RNAi, the misfolded α-syn::GFP returns (c). d-f. Over-
expression of CD protects DA neurons from α-syn-induced degeneration. Worm DA neurons degenerate as animals age. At 
the 7 d stage, most worms are missing anterior DA neurons of the CEP (cephalic) and/or ADE (anterior deirid) classes. d. 
Note the presence of 3 of 4 CEP DA neurons (arrows) and the absence of the 2 ADE neurons. e. Overexpression of CD pro-
tects worms from neurodegeneration whereby worms display all 4 CEP (arrows) and both ADE (arrowheads) neurons. f. 
RNAi knock down of asp-4 does not reduce tor-2 expression level. Semi-quantitative RT-PCR was performed by using primers 
to amplify cdk-5 (loading control) and tor-2. For all strains analyzed, normal (non-RNAi) condition was used as a negative con-
trol, and tor-2 RNAi was used as a positive control.g. The percentage of worms exhibiting the wildtype neuronal complement 
of all 6 anterior DA neurons (30%) was significantly greater than animals without CD overexpression (15%). CD mutants 
(D295R and F229I), CB and CL, in transgenic worms overexpressing human cDNAs encoding these mutated CD or the repre-
sentative lysosomal cysteine proteases, do not have the same effect as the wildtype CD in reducing α-syn toxicity. *p < 0.001 
compared to α-syn alone, by Fisher Exact Test.Molecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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Methods
Mice
We genotyped littermates from Ctsd+/- breeding. We used
Ctsd+/+, Ctsd+/- and Ctsd-/- littermates on C57BL6 back-
ground for all experiments.
Immunohistochemistry
Brains were placed in Bouin's fixative overnight at 4°C
followed by paraffin embedding. 5 μm thick sections were
used for immunohistochemical studies. The following
antibodies were used: mouse anti-NeuN (Chemicon),
mouse anti-α-syn (BD Transduction Lab), sheep anti-α-
syn (Chemicon), goat anti-CD (Santa Cruz), mouse anti-
GFAP (Chemicon), rabbit anti-Ub (Dako), mouse anti-
Ub (FK2, Biomol), mouse anti-Ub (Chemicon, clone Ubi-
1), mouse anti-Ub (Zymed), mouse anti-synaptophysin
(Chemicon), goat anti-cathepsin B (Santa Cruz), rabbit
anti-active caspase 3 (Chemicon), and rabbit-anti-
GAPDH (Cell Signaling). Horseradish peroxidase conju-
gated donkey derived secondary antibodies were used at
1:2000 (Jackson ImmunoResearch). The sections were
then incubated with tyramide signal amplification (TSA)
plus detection solution with Cy3 or fluorescein tyramide
according to the manufacturer's instruction (PerkinElmer
Life Sciences), followed by bisbenzimide staining of DNA.
For chromogenic immunohistochemistry, we incubated
the sections with a biotinylated secondary antibody (Vec-
tor Laboratories) followed by ABC reagent (ABC kit, Vec-
tor Laboratories). We visualized the immunoreaction by
treating the sections in 0.05% diaminobenzidine (DAB)
with hydrogen peroxide. The images were taken using a
Leica TCS SP5 confocal microscope or a Zeiss Axiocam
CCD camera on a 100 W Axioscope bright field and fluo-
rescence microscope.
α-syn aggregation assay
We used the in vitro system developed by McLean and col-
leagues in which an α-syn-green fluorescent protein
(GFP) fusion protein (α-syn-GFP) becomes truncated at
the C-terminus, cleaving off GFP, to form visible aggre-
gates in cells when co-expressed with synphilin[41]. We
transfected H4 neuroglioma cells with α-syn-GFP and
synphilin, and either the empty vector pcDNA3.1 or CD.
24 h after transfection, cells were fixed and stained with a
mouse monoclonal antibody against α-syn (1:1000; BD
transduction), and a secondary Alexa 488-conjugated goat
anti-mouse antibody (1:500; Jackson ImmunoResearch).
An observer blind to the transfection conditions scored
neurons as positive or negative for α-syn aggregates visible
with a 20X objective under a fluorescent microscope.
Three independent experiments were carried out with 4
replicates per experiment. Student t-test was used to com-
pare transfection with empty vector versus transfection
with CD.
Cell culture and transfection
The human neuroblastoma SHSY5Y cells were transfected
in triplicate by vector alone, a-syn-GFP, pCMV-CD, or co-
transfected by a-syn-GFP (or A53T, A30P, Y125A mutant
a-syn) and pCMV-CD (or mutant CD) by Amaxa method
as described by the vendor. Transfection efficiency was
80% as assessed by cells with or without GFP. 72 h after
transfection, cells were harvested. For chloroquine (10
mM) treatment, the chemicals were added 48 h after
transfection, cells were harvested 42 h later. Live cells were
counted by trypan blue exclusion. Relative cell survival
was calculated as number of live cells after transfection by
pCMV-CD and/or a-syn-GFP divided by live cells after
transfection by vector alone. Elevated expression of a-syn-
GFP or cathepsins was confirmed by western blot analyses
using whole cell extracts.
Western blot
We homogenized wildtype and Ctsd-/- cortex (n ≥ 3 each
genotype) in 10 volumes of ice-cold lyses buffer (50 mM
Tris-HCl pH 7.4, 175 mM NaCl, 5 mM EDTA), sonicated
for 10 sec, add TritonX-100 to 1% and incubated for 30
min on ice. We then centrifuged homogenates at 15,000 g
for 15 min at 4°C to separate supernatants (fractions sol-
uble in 1% TritonX-100) and pellets (TritonX-100-insolu-
ble fractions)[43]. Pellets were resuspended in lyses buffer
containing 2% SDS. Western blotting for each sample was
done at least twice. The antibodies used were described in
Immunohistochemistry.
Quantitative PCR
Total brain RNA was isolated from p25 mice using RNA-
STAT60 (Tel-Test, Friendswood, TX). Total RNA (2 μg)
was then reverse transcribed using Applied Biosystems
GeneAmp Gold RNA PCR Reagent Kit (Foster City, CA).
Real-time PCR reactions were setup in duplicate using
TaqMan gene assays and amplified in an Applied Biosys-
tems Step-One instrument. ΔΔCCT curves were generated
using 18S TaqMan gene assays as internal standards.
Quantitative PCR results are shown as standard deviation
of from 3 different amplifications from RNA reverse tran-
scribed from 3 different animals. Individual gene assay
kits were purchased from Applied Biosystems for each of
the RNAs analyzed. Paired t-tests were conducted on RQ
(relative quantity) values for each group to determine sig-
nificance.
Proteasome activity assays
We analyzed the proteasome activities using the TritonX-
100-soluble fractions. The assay buffer consists of 50 mM
Tris (pH7.5), 2.5 mM EGTA, 20% glycerol, 1 mM DTT,
0.05% NP-40, 50 μM substrate. Lactacystin was used at a
final concentration of 10 μM to block proteasome activi-
ties as negative controls. Fluorescence was read at 5 min
intervals for 2 h, at an excitation wavelength of 380 nmMolecular Brain 2008, 1:17 http://www.molecularbrain.com/content/1/1/17
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and an emission wavelength of 460 nM. Assays were done
in triplicate, each using n ≥ 3 mice per genotype.
C. elegans experiments
Nematodes were maintained following standard proce-
dures[69]. Worms expressing α-syn alone UA49 [baInl2;
Punc-54::α-syn::gfp,  rol-6 (su1006)] or with tor-2  [UA50;
baInl3; Punc-54::α-syn::gfp, Punc-54::tor-2, rol-6 (su1006)] were
created, integrated into the genome to generate an iso-
genic line, and out-crossed four times. We used the worm
line that overexpresses TOR-2 protein (a worm homolog
of human torsinA) and a-syn fused to GFP in the body
wall muscle cells because these cells are much larger than
neurons for detecting a-syn aggregation. Moreover, C. ele-
gans dopaminergic neurons have been shown to be refrac-
tory to RNAi. Using this isogenic line, we knocked down
the worm Ctsd ortholog by RNAi, and scored for the
return of a-syn aggregates over the course of development
and aging.
RNAi was performed by bacterial feeding as described[70]
with the following modification. A Ctsd-specific RNAi
feeding clone targeting a distinct portion of the C. elegans
open reading frame [R12H7.2 (asp-4); e-value = 1.8e-108]
with highest homology to human Ctsd (Geneservice) was
grown for 14 h in LB broth with 100 μg/ml ampicillin and
seeded onto NGM agar plates containing 1 mM isopropyl
β-D-thiogalactoside. After 4 h incubation at 25°C to dry
the plates, five gravid adults were then placed onto the
corresponding RNAi plates and allowed to lay eggs for 9
h; the resulting age-synchronized worms were analyzed at
the indicated stage. RNAi knockdown was performed in
duplicate sets of animals and enhancement α-syn mis-
folding was scored as positive if at least 80% of worms dis-
played an increased quantity and size of α-syn::GFP
aggregates. For each trial, 20 worms were transferred onto
a 2% agarose pad, immobilized with 2 mM levamisole,
and analyzed using Nikon Eclipse E800 epifluorescence
microscope equipped with Endow GFP HYQ filter cube
(Chroma Technology). Images were captured with a Cool
Snap CCD camera (Photometrics) driven by MetaMorph
software (Universal Imaging).
Quantitative PCR from C. elegans
The procedure for total RNA isolation, cDNA preparation,
and semi-quantitative RT-PCR was described previ-
ously[71]. The following primers were used for the PCR:
cdk-5 Primer 1: 5' ggg-gat-gat-gag-ggt-gtt-cca-agc 3'; Primer
2: 5' ggc-gac-cgg-cat-ttg-aga-tct-ctg-c 3'. tor-2 Primer 1: 5'
caa-tta-tca-tgc-gtt-ata-caa-ag 3'; Primer 2: 5' cat-tcc-act-tcg-
ata-agt-att-g 3'. cdk-5 Primer 1: 5' ggg-gat-gat-gag-ggt-gtt-
cca-agc 3'; Primer 2: 5' ggc-gac-cgg-cat-ttg-aga-tct-ctg-c 3'.
tor-2 Primer 1: 5' caa-tta-tca-tgc-gtt-ata-caa-ag 3'; Primer 2:
5' cat-tcc-act-tcg-ata-agt-att-g 3'.
For the DA neurodegeneration analysis, strain UA54
[baEx45; Pdat-1::α-syn, Pdat-1::gfp, Pdat-1::CD,rol-6 (su1006)],
UA90 [baEx69;  Pdat-1::α-syn, Pdat-1::gfp, Pdat-1::CD
D295R,rol-6 (su1006)], UA91 [baEx70; Pdat-1::α-syn, Pdat-
1::gfp, Pdat-1::CD F229I,rol-6 (su1006)], UA53 [baEx44; Pdat-
1::α-syn, Pdat-1::gfp, Pdat-1::CB,rol-6 (su1006)], and UA55
[baEx46; Pdat-1::α-syn, Pdat-1::gfp, Pdat-1::CL,rol-6 (su1006)]
were generated by injecting 50 μg/ml of expression plas-
mid containing the human cathepsin cDNA and 50 μg/ml
of rol-6 into an integrated line of UA44 [baInl1; Pdat-1::α-
syn, Pdat-1::gfp[72]]. Three stable lines were randomly
selected for neurodegeneration analysis. The 6 anterior
DA neurons (4 CEP and 2 ADE neurons) of 30 animals/
trial were examined for neurodegeneration when the ani-
mals were 7 days old. 90 animals from each of three CD
(or CD D295R, CD F229I, CB, and CL) transgenic lines
were analyzed (3 lines × 3 trials of 30 animals/trial = 270
total animals scored). Worms displaying at least one
degenerative change (dendrite, axon, or cell body loss)
were scored as exhibiting degenerating neurons as previ-
ously reported [44;72].
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